Testing the usefulness of the number needed to treat to be harmed (NNTH) in benefit-risk evaluations: case study with medicines withdrawn from the European market due to safety reasons
出版年份 2016 全文链接
标题
Testing the usefulness of the number needed to treat to be harmed (NNTH) in benefit-risk evaluations: case study with medicines withdrawn from the European market due to safety reasons
作者
关键词
-
出版物
Expert Opinion On Drug Safety
Volume 15, Issue 10, Pages 1301-1312
出版商
Informa UK Limited
发表日期
2016-07-29
DOI
10.1080/14740338.2016.1217989
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Number needed to harm in the post-marketing safety evaluation: results for rosiglitazone and pioglitazone
- (2015) Diogo Mendes et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- Drug-safety alerts issued by regulatory authorities: usefulness of meta-analysis in predicting risks earlier
- (2014) Carlos Alves et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients
- (2014) NEW ENGLAND JOURNAL OF MEDICINE
- Balancing benefit and risk of medicines: a systematic review and classification of available methodologies
- (2014) Shahrul Mt-Isa et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- Impact of Inclusion of Industry Trial Results Registries as an Information Source for Systematic Reviews
- (2014) Regine Potthast et al. PLoS One
- Differences in reporting serious adverse events in industry sponsored clinical trial registries and journal articles on antidepressant and antipsychotic drugs: a cross-sectional study
- (2014) S. Hughes et al. BMJ Open
- Quality of reporting in systematic reviews of adverse events: systematic review
- (2014) L. Zorzela et al. BMJ-British Medical Journal
- A Primer on Effectiveness and Efficacy Trials
- (2014) Amit G Singal et al. Clinical and Translational Gastroenterology
- The Future of Population-Based Postmarket Drug Risk Assessment: A Regulator’s Perspective
- (2013) T A Hammad et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Sources of information used by regulatory agencies on the generation of drug safety alerts
- (2013) Carlos Alves et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- When does a difference make a difference? Interpretation of number needed to treat, number needed to harm, and likelihood to be helped or harmed
- (2013) L. Citrome et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Cardiovascular Effects of Intensive Lifestyle Intervention in Type 2 Diabetes
- (2013) NEW ENGLAND JOURNAL OF MEDICINE
- Comparison of Pooled Risk Estimates for Adverse Effects from Different Observational Study Designs: Methodological Overview
- (2013) Su Golder et al. PLoS One
- Clinical study reports of randomised controlled trials: an exploratory review of previously confidential industry reports
- (2013) Peter Doshi et al. BMJ Open
- Echocardiographic Evidence for Valvular Toxicity of Benfluorex: A Double-Blind Randomised Trial in Patients with Type 2 Diabetes Mellitus
- (2012) Geneviève Derumeaux et al. PLoS One
- Drug safety assessment in clinical trials: methodological challenges and opportunities
- (2012) Sonal Singh et al. Trials
- Data sources on drug safety evaluation: a review of recent published meta-analyses
- (2011) Carlos Alves et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- Rosiglitazone Revisited
- (2010) Steven E. Nissen et al. ARCHIVES OF INTERNAL MEDICINE
- The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: A retrospective cohort study using a US health insurance database
- (2010) Najat Ziyadeh et al. CLINICAL THERAPEUTICS
- Rosiglitazone: a European regulatory perspective
- (2010) E. Blind et al. DIABETOLOGIA
- Risk of Acute Myocardial Infarction, Stroke, Heart Failure, and Death in Elderly Medicare Patients Treated With Rosiglitazone or Pioglitazone
- (2010) David J. Graham et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects
- (2010) W. Philip T. James et al. NEW ENGLAND JOURNAL OF MEDICINE
- Benfluorex and valvular heart disease: a cohort study of a million people with diabetes mellitus
- (2010) Alain Weill et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- Relative vs. absolute measures of benefit and risk: whatâs the difference?
- (2009) L. Citrome ACTA PSYCHIATRICA SCANDINAVICA
- Flushing Profile of Extended-Release Niacin/Laropiprant Versus Gradually Titrated Niacin Extended-Release in Patients With Dyslipidemia With and Without Ischemic Cardiovascular Disease
- (2009) Darbie Maccubbin et al. AMERICAN JOURNAL OF CARDIOLOGY
- Communicating benefit and risk
- (2009) Trevor Baglin BRITISH JOURNAL OF HAEMATOLOGY
- Rapid Identification of Myocardial Infarction Risk Associated With Diabetes Medications Using Electronic Medical Records
- (2009) J. S. Brownstein et al. DIABETES CARE
- Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial
- (2009) Philip D Home et al. LANCET
- Comparison of Cardiovascular Outcomes in Elderly Patients With Diabetes Who Initiated Rosiglitazone vs Pioglitazone Therapy
- (2008) Wolfgang C. Winkelmayer et al. ARCHIVES OF INTERNAL MEDICINE
- Is there evidence for biased reporting of published adverse effects data in pharmaceutical industry-funded studies?
- (2008) Su Golder et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia
- (2008) D. Maccubbin et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Benefits and Risks of Drug Treatments
- (2008) Jan P. Vandenbroucke et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Effect of Rimonabant on Progression of Atherosclerosis in Patients With Abdominal Obesity and Coronary Artery Disease
- (2008) Steven E. Nissen et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Coronary heart disease outcomes in patients receiving antidiabetic agents in the PharMetrics database 2000-2007
- (2008) Alexander M. Walker et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- Safety assessment of new antithrombotic agents: Lessons from the EXTEND study on ximelagatran
- (2008) G. Agnelli et al. THROMBOSIS RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started